Clinical Trials Logo

Diabetic Retinopathy clinical trials

View clinical trials related to Diabetic Retinopathy.

Filter by:

NCT ID: NCT00853424 Withdrawn - Clinical trials for Diabetic Retinopathy

A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease

Start date: December 2009
Phase: Phase 3
Study type: Interventional

Diabetic eye disease remains a major cause of visual loss for individuals with type 1 diabetes, despite currently available treatments. Preliminary studies indicate that islet cell transplantation, a new treatment for type 1 diabetes, may be beneficial for some people. This study is designed to test the hypothesis that islet cell transplantation is more effective than current medical therapy in preventing the progression of diabetic eye disease.

NCT ID: NCT00600236 Withdrawn - Clinical trials for Diabetes Mellitus Type 2

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Start date: September 2004
Phase: Phase 3
Study type: Interventional

One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

NCT ID: NCT00496405 Withdrawn - Clinical trials for Diabetic Retinopathy

Unilateral Bevacizumab for Bilateral Diabetic Macular Edema

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The endothelial growth factor (VEGF), has been implied in the genesis of diverse Neovascular disease. In the industrialized and developing countries, the main cause of blindness is the diabetic retinopathy. Bevacizumab (Avastin, genentech, Inc., San Francisco, California, the USA) is a drug.In the last years its use "off-label", in ophthalmology field, has become popular. This is due to its proven safeness and effectiveness for the treatment of diverse ocular diseases. A lot has been speculated about the systemic absorption of Bevacizumab. It is for that reason that the objective of this study is the systematic and random revision of the fellows eyes, of the patients programmed for the intravitreal administration of Bevacizumab, with bilateral macular edema. In such a way that the therapeutic value in the fellow eye of bevacizumab can be determined

NCT ID: NCT00457470 Withdrawn - Diabetes Mellitus Clinical Trials

A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)

Start date: June 2007
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of AG-014699 in diabetic patients

NCT ID: NCT00407108 Withdrawn - Clinical trials for Diabetic Retinopathy

Perfluorocarbon Perfused Vitrectomy and 3D Vitrectomy System in Advanced Diabetic Retinopathy

Start date: March 2006
Phase: Phase 3
Study type: Interventional

To investigate the feasibility and advantages of using perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting vitrectomy using a dual, dynamic drive (3D)technology. In complicated surgeries in advanced diabetic retinopathy and retinal detachment

NCT ID: NCT00347698 Withdrawn - Clinical trials for Diabetic Retinopathy

Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy

Start date: March 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of patients with untreated symmetric proliferative diabetic retinopathy.